Trade Names:Vivaglobin- Injection 160 mg/mL
Replaces normal human IgG antibodies.
Bioavailability of immune globulin (IG) subcutaneous is approximately 73% compared with IG intravenous (IGIV). Peak serum IgG levels are lower with subcutaneous compared with IV administration. Mean peak and trough IgG levels following subcutaneous administration are 1,163 and 1,064 mg/dL, respectively.
Steady-state serum IgG levels are relatively stable with weekly subcutaneous administration.
Mean t ½ is at least 21 days.
Treatment of primary immune deficiency.
History of anaphylactic or severe systemic response to IG preparations; patients with selective immunoglobulin A (IgA) deficiency who have known antibody against IgA.
Subcutaneous Recommended weekly dose is 100 to 200 mg/kg body weight. Calculate the initial weekly dose by multiplying the previous IGIV dose by 1.37 then divide this dose into weekly doses based on the previous IGIV treatment interval. Doses may be adjusted over time to achieve the desired clinical response and serum IgG levels.
Store in refrigerator (36° to 46°F). Do not freeze.
Efficacy of live attenuated virus vaccines may be transiently impaired.
Passive transmission of antibodies to erythrocyte antigens (eg, A, B, D) may cause a positive direct or indirect antiglobulin test.
Headache (48%); asthenia (5%).
Rash (17%); skin disorder (3%); mild or moderate swelling, redness, and itching.
Sore throat (17%).
GI disorder (37%); nausea (11%); diarrhea (10%).
Urine abnormality (3%).
Increased cough (10%).
Fever (25%); allergic reaction (11%); pain (10%).
Category C .
Safety and efficacy not established in children younger than 2 yr of age.
Hypersensitivity, including anaphylactic reactions may occur.
Patients receiving IG therapy for the first time, switching from another brand of IG, or who have not received IG within the preceding 8 wk may be at risk for developing reactions including chills, fever, nausea, vomiting, and rarely shock.
IG subcutaneous is made from human blood and may carry a risk of transmitting infectious agents (eg, Creutzfeldt-Jakob disease, viruses).
No data available.
Copyright © 2009 Wolters Kluwer Health.